<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/23/hookipa-pharma-inc-nasdaqhook-receives-consensus-recommendation-of-buy-from-brokerages.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-23T21:51:03+00:00"/>
    <meta property="og:title" content="Hookipa Pharma Inc (NASDAQ:HOOK) Receives Consensus Recommendation of “Buy” from Brokerages"/>
    <meta property="og:description" content="Shares of Hookipa Pharma Inc (NASDAQ:HOOK) have received a consensus rating of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that […]"/>
  </head>
  <body>
    <article>
      <h1>Hookipa Pharma Inc (NASDAQ:HOOK) Receives Consensus Recommendation of “Buy” from Brokerages</h1>
      <address><time datetime="2019-11-23T21:51:03+00:00">23 Nov 2019, 21:51</time> by <a rel="author" href="https://www.thecerbatgem.com/author/jessica" target="_blank">Jessica Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Shares of Hookipa Pharma Inc (NASDAQ:HOOK) have received a consensus rating of “Buy” from the seven research firms that are covering the stock, <a href="https://www.marketbeat.com/">Marketbeat.com</a> reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $18.40.</p>
      <p>A number of analysts have recently weighed in on HOOK shares. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=HOOK">ValuEngine</a> raised Hookipa Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Hookipa Pharma in a research note on Wednesday, November 13th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> lowered Hookipa Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Royal Bank of Canada reissued a “buy” rating and set a $23.00 price objective on shares of Hookipa Pharma in a research note on Wednesday, August 14th. Finally, Bank of America dropped their price objective on Hookipa Pharma from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.</p>
      <p>Institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC bought a new position in shares of Hookipa Pharma during the second quarter valued at $40,000. Northern Trust Corp bought a new stake in Hookipa Pharma in the 2nd quarter worth about $72,000. First Trust Advisors LP bought a new stake in Hookipa Pharma in the 3rd quarter worth about $103,000. Morgan Stanley bought a new stake in Hookipa Pharma in the 2nd quarter worth about $99,000. Finally, Vanguard Group Inc. bought a new stake in Hookipa Pharma in the 2nd quarter worth about $538,000. 30.52% of the stock is owned by institutional investors and hedge funds.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/HOOK/price-target/">NASDAQ HOOK</a> traded up $0.20 during trading on Friday, hitting $8.45. 19,000 shares of the company’s stock traded hands, compared to its average volume of 36,592. Hookipa Pharma has a 12-month low of $6.06 and a 12-month high of $14.76. The company has a debt-to-equity ratio of 0.08, a current ratio of 10.53 and a quick ratio of 10.53. The business has a 50 day moving average of $7.81 and a 200-day moving average of $8.15.</p>
      <p>Hookipa Pharma (NASDAQ:HOOK) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.21. The business had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.35 million. Research analysts predict that Hookipa Pharma will post -2.13 earnings per share for the current year.</p>
      <p>
        <b>Hookipa Pharma Company Profile</b>
      </p>
      <p>HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/what-member-countries-make-up-the-g-20/">What is the role of the G-20?</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=HOOK"/>
      </figure>
    </article>
  </body>
</html>